BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37352112)

  • 1. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
    Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P
    Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
    Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
    ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.
    Vakilpour A; Lefebvre B; Lai C; Scherrer-Crosbie M
    Blood Rev; 2024 Mar; 64():101166. PubMed ID: 38182490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction to: Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Eur J Prev Cardiol; 2023 Dec; 30(18):2044. PubMed ID: 37699074
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study.
    Hubbert L; Mallios P; Karlström P; Papakonstantinou A; Bergh J; Hedayati E
    Front Oncol; 2023; 13():1095251. PubMed ID: 37152049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of haematologic malignancies and survival outcomes of adult lymphomas in Maiduguri, north eastern Nigeria--a fourteen year review.
    Kagu MB; Ahmed SG; Bukar AA; Mohammed AA; Mayun AA; Musa AB
    Afr J Med Med Sci; 2013 Mar; 42(1):5-14. PubMed ID: 23909089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
    Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
    Kristensen LE; Strober B; Poddubnyy D; Leung YY; Jo H; Kwok K; Vranic I; Fleishaker DL; Fallon L; Yndestad A; Gladman DD
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X221149965. PubMed ID: 36777695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
    de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Italian cancer figures, report 2012: Cancer in children and adolescents.
    ; ;
    Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
    Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
    Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
    Lancellotti P; Anker SD; Donal E; Edvardsen T; Popescu BA; Farmakis D; Filippatos G; Habib G; Maggioni AP; Jerusalem G; Galderisi M
    Eur Heart J Cardiovasc Imaging; 2015 May; 16(5):466-70. PubMed ID: 25744342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival for patients with rare haematologic malignancies: Changes in the early 21st century.
    Pulte D; Weberpals J; Jansen L; Luttmann S; Holleczek B; Nennecke A; Ressing M; Katalinic A; Brenner H;
    Eur J Cancer; 2017 Oct; 84():81-87. PubMed ID: 28800491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.